1. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease (HD) treated with a modified BEACOPP regimen is probably related to the combination of gemcitabine and bleomycin;Bredenfeld;Ann Oncol,2002
2. Fludarabine versus CVP in newly diagnosed patients with stages III/IV non-Hodgkin's lymphoma. Final analysis of prospective randomized phase III inter-group study;Marcus;Ann Oncol,2002
3. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998
4. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma;Hainsworth;Proc Am Soc Clin Oncol,2001
5. Rituximab as single first-line therapy for patients with follicular lymphomas with a low tumour burden: clinical and molecular evaluation;Colombat;Blood,2001